Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

Finasteride 1mg helps reverse hair miniaturization in men and postmenopausal women.

This study found that the retinoid receptor and PPAR pathway are involved in hair follicle miniaturization in androgenetic alopecia, alongside androgen receptors.

New method, hair distribution width (HDW), improves accuracy in diagnosing androgenetic alopecia (AGA).

In this small, non-randomized study, researchers reported that injecting hair-follicle-derived stem cells into the scalps of androgenetic alopecia patients improved hair density and caliber compared to a control group, suggesting potential efficacy of this approach; however, larger, randomized studies are needed to confirm these findings.

Ludwig pattern hair loss results from varying androgen sensitivity, causing fewer thick hairs and more thin hairs.

This study suggests that miniaturization in pattern hair loss may occur abruptly and can be reversed with treatment, as supported by histologic evidence in finasteride-responsive patients.

This review proposes that inconsistent findings in androgenic alopecia research are due to variable biopsy location, hair diameter diversity, and hair follicle miniaturization, and suggests ways to improve study methods.

This study found that the DKK3-CKAP4 signaling axis is involved in fibroimmune remodeling in androgenetic alopecia and that targeting this pathway may restore a regenerative hair follicle environment, offering a potential therapeutic strategy to counteract hair follicle miniaturization.

This study observed that fibrosis occurs in the bulge region of hair follicles affected by androgenetic alopecia and is correlated with the hair miniaturization process.

This study found that women with androgenetic alopecia experience diffuse hair loss due to a decrease in terminal hairs and an increase in vellus hairs per follicular unit.

This systematic review concluded that dutasteride was more effective than finasteride in increasing hair count for treating androgenetic alopecia in both males and females, with comparable side effects.

In this randomized, controlled trial, the researchers observed that sub-lingual minoxidil at doses of 1.35 mg and 4.05 mg, but not 0.45 mg, significantly increased hair fibre diameter in men with male androgenetic alopecia over 24 weeks, suggesting a dose-dependent reversal of follicle miniaturization.

This study suggests that impaired autophagy may be a potential mechanism contributing to androgenetic alopecia, as observed in miniaturized hair follicles from balding scalps.

This study found that loss of contact between the arrector pili muscle and the hair follicle bulge may explain why hair loss in male and female pattern baldness is largely irreversible, unlike in alopecia areata.

This document supplements a study on androgenetic alopecia, describing materials and methods, and includes figures showing fibrosis in the bulge region of miniaturized hair follicles.

This study proposes a new clinical scoring method for hair density based on hair diameter diversity, which correlates with existing measures and reflects follicle miniaturization in androgenetic alopecia.

This study found that in androgenic alopecia, the arrector pili muscle degenerates and is replaced by fat, unlike in normal skin or telogen effluvium.

This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.

This review discusses recent research on androgenetic alopecia's etiology and pathogenesis, highlighting both androgenic and nonandrogenic factors but reports no new experimental results.

This article explores whether it's possible to stop the progression of male androgenetic alopecia without using antiandrogenic drugs and reports no new clinical findings.

In this study, the researchers reported that a novel exosome-based treatment, EX104, effectively reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, showing results comparable to minoxidil and surpassing it in stimulating capillary growth and follicular proliferation.

This study reviews the effectiveness, viability, and safety of minoxidil and finasteride in treating androgenetic alopecia in women, aiming to provide insights for better management of this condition based on bibliographic comparisons.

In this study, the researchers found that the ethyl acetate fraction of Sansevieria trifasciata P. (20%) was just as effective as minoxidil (2%) in promoting hair growth in male rabbits, with notable results in hair follicle proliferation and a favorable anagen to telogen ratio.

This review outlines the optimization of platelet concentrates for hair loss treatment and suggests extracellular vesicles as a key future element, aiming to advance point-of-care regenerative therapies despite the need for a unified framework and further research on underlying mechanisms.

This review synthesizes current knowledge on hair follicle biology in androgenetic alopecia and explores potential regenerative therapies, but it reports no new clinical results.

This narrative review explores molecular signaling pathways and their impact on hair follicle microenvironments in androgenetic alopecia, alongside potential treatments like stromal vascular fraction therapies and exosome-based strategies.

This review integrates current understanding of hair follicle biology and signaling pathways into a comprehensive framework for androgenetic alopecia, but presents no new empirical findings.

Hair diameter diversity could improve androgenetic alopecia assessment and treatment planning.

This review discusses the complex genetic factors contributing to androgenetic alopecia, highlighting the variability in genetic risk across different populations and the emerging understanding of personalized treatment strategies, but reports no new clinical findings.